[
  {
    "ts": null,
    "headline": "Trump Triggered a Rally in Drug Stocks. Why It Might Not Last.",
    "summary": "The surge in pharmaceutical stocks that followed the administration’s deal with Pfizer on Tuesday was still going strong on Wednesday.",
    "url": "https://finnhub.io/api/news?id=13f5eb24fffe0cf0e1dabf1387b42196ba46fe57fd37f6076214bb13b7713c62",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759346340,
      "headline": "Trump Triggered a Rally in Drug Stocks. Why It Might Not Last.",
      "id": 136952146,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "The surge in pharmaceutical stocks that followed the administration’s deal with Pfizer on Tuesday was still going strong on Wednesday.",
      "url": "https://finnhub.io/api/news?id=13f5eb24fffe0cf0e1dabf1387b42196ba46fe57fd37f6076214bb13b7713c62"
    }
  },
  {
    "ts": null,
    "headline": "Kymera Overcomes Sanofi Deal Update, Marches Ahead With Pipeline",
    "summary": "Kymera advances its protein degradation pipeline with new Sanofi and Gilead deals, milestone payouts, and promising trial updates.",
    "url": "https://finnhub.io/api/news?id=f556f3da427373e859030713166b5ba9779250e577a5ee430238c15fd49369c8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759325880,
      "headline": "Kymera Overcomes Sanofi Deal Update, Marches Ahead With Pipeline",
      "id": 136947454,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "Kymera advances its protein degradation pipeline with new Sanofi and Gilead deals, milestone payouts, and promising trial updates.",
      "url": "https://finnhub.io/api/news?id=f556f3da427373e859030713166b5ba9779250e577a5ee430238c15fd49369c8"
    }
  },
  {
    "ts": null,
    "headline": "Immatics Appoints Venkat Ramanan as Chief Financial Officer",
    "summary": "Houston, Texas and Tuebingen, Germany, October 1, 2025 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), a clinical-stage biopharmaceutical company and the global leader in precision targeting of PRAME, today announced the appointment of Venkat Ramanan, Ph.D., as Chief Financial Officer (“CFO”), effective immediately. Dr. Ramanan is a seasoned financial leader in the biopharmaceutical industry with over 25 years of experience at companies including Seagen, Gilead Sciences and Amgen. H",
    "url": "https://finnhub.io/api/news?id=f3a8b72fa762162bd3b59636b253655a37df2d960060e0b9431f44c3cc406dcd",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759316400,
      "headline": "Immatics Appoints Venkat Ramanan as Chief Financial Officer",
      "id": 136944222,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "Houston, Texas and Tuebingen, Germany, October 1, 2025 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), a clinical-stage biopharmaceutical company and the global leader in precision targeting of PRAME, today announced the appointment of Venkat Ramanan, Ph.D., as Chief Financial Officer (“CFO”), effective immediately. Dr. Ramanan is a seasoned financial leader in the biopharmaceutical industry with over 25 years of experience at companies including Seagen, Gilead Sciences and Amgen. H",
      "url": "https://finnhub.io/api/news?id=f3a8b72fa762162bd3b59636b253655a37df2d960060e0b9431f44c3cc406dcd"
    }
  },
  {
    "ts": null,
    "headline": "2 Nasdaq 100 Stocks on Our Watchlist and 1 We Brush Off",
    "summary": "The Nasdaq 100 (^NDX) is known for housing some of the most innovative and fastest-growing companies in the market. But not every stock in the index is a winner - some are struggling with slowing growth, increasing competition, or unsustainable valuations.",
    "url": "https://finnhub.io/api/news?id=44e78efe5238fac54f182311e8f469a7303fee90f6f52ae4be3049c3987beb2e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759293088,
      "headline": "2 Nasdaq 100 Stocks on Our Watchlist and 1 We Brush Off",
      "id": 136947455,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "The Nasdaq 100 (^NDX) is known for housing some of the most innovative and fastest-growing companies in the market. But not every stock in the index is a winner - some are struggling with slowing growth, increasing competition, or unsustainable valuations.",
      "url": "https://finnhub.io/api/news?id=44e78efe5238fac54f182311e8f469a7303fee90f6f52ae4be3049c3987beb2e"
    }
  }
]